NeOnc Technologies Holdings is seeking FDA development pathways for its products, utilizing the Fast Track designation, and is listed on Nasdaq.
2 reports, 2 independent
Updated Aug 11
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 3
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
NeOnc Technologies Holdings is seeking FDA development pathways for its products, utilizing the Fast Track designation, and is listed on Nasdaq.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- NeOnc Technologies was listed on Nasdaq and filed a purchase disclosure with the SEC.Sub-event
- Market attention is focused on NeOnc Technologies Holdings due to positive clinical trial results and discussions regarding the path toward a registrational study.Sub-event
NeOnc is seeking FDA development pathways and utilizing Fast Track designation.1 source
Keep exploring
The entities involved
- FDA
-
Nasdaq
American fully electronic stock exchange
-
Fast Track
American company
Nothing else this week.
Related events
- Iovance Biotherapeutics listed its stock on Nasdaq and received Fast Track designation from the FDA.
- Cardiol Therapeutics Inc. is listed on Nasdaq and is developing therapy for an FDA-approved indication.
- Decoy Therapeutics is listed on the Nasdaq stock exchange and is currently seeking expedited regulatory approval via FDA pathways.
- Orchestra BioMed Holdings, Inc. is listed on Nasdaq, and various investment firms including BlackRock, UBS AM, and others have purchased new stakes in the company.
- Mylan is seeking regulatory approval from the FDA for new products and has listed its stock on the Nasdaq exchange.